Diamondbacks' Corbin Burnes leaves game against the Nationals with an apparent injury
Arizona Diamondbacks pitcher Corbin Burnes, left, leaves a baseball game against the Washington Nationals in the fifth inning Sunday, June 1, 2025, in Phoenix. (AP Photo/Rick Scuteri)
Arizona Diamondbacks pitcher Corbin Burnes throws against the Washington Nationals in the first inning during a baseball game, Sunday, June 1, 2025, in Phoenix. (AP Photo/Rick Scuteri)
Arizona Diamondbacks pitcher Corbin Burnes throws against the Washington Nationals in the first inning during a baseball game, Sunday, June 1, 2025, in Phoenix. (AP Photo/Rick Scuteri)
Arizona Diamondbacks pitcher Corbin Burnes, left, leaves a baseball game against the Washington Nationals in the fifth inning Sunday, June 1, 2025, in Phoenix. (AP Photo/Rick Scuteri)
Arizona Diamondbacks pitcher Corbin Burnes throws against the Washington Nationals in the first inning during a baseball game, Sunday, June 1, 2025, in Phoenix. (AP Photo/Rick Scuteri)
PHOENIX (AP) — Arizona Diamondbacks ace Corbin Burnes was lifted after just 70 pitches Sunday against Washington with an apparent injury.
Arizona led 3-0 in the top of the fifth when Burnes allowed a single by C.J. Abrams with two outs. The right-hander then gestured toward the dugout with his glove and yelled in frustration.
Advertisement
Jalen Beeks replaced Burnes and gave up an RBI single before getting the third out.
Burnes allowed a run and four hits in 4 2/3 innings, with a walk and six strikeouts. He's 3-2 with a 2.66 ERA in 11 starts on the season.
Arizona signed Burnes to a $210 million, six-year contract before the season. He's been effective, but the Diamondbacks have dealt with a slew of pitching injuries. Jordan Montgomery (Tommy John surgery) is out for the season, Eduardo Rodríguez (shoulder) is on the injured list, and reliever A.J. Puk (elbow) is on the IL as well.
Arizona allowed 10 runs in the first inning Saturday, its ninth loss in 10 games.
___
AP NHL: https://www.apnews.com/hub/MLB
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Why six hours of sleep is not enough
For those of us who worry about our sleep, every morning is a scramble of mental maths as we turn to our bedside clock and calculate whether or not we've had 'enough'. The current National Sleep Foundation guidelines recommend that most adults sleep for between seven and nine hours per night. This followed a 2022 paper from the University of Cambridge, itself an amalgam of hundreds of studies that followed people's long-term experience of heart disease, diabetes and mental-health difficulties. 'Having a consistent seven hours' sleep each night, without too much fluctuation in duration, was also important to cognitive performance and good mental health and wellbeing,' say the authors of the paper. Those who slept between seven and nine hours reported a lower incidence of these chronic conditions. But what if, for any reason, you consistently don't sleep that much? If you have trouble sleeping, or if you just want to jump onto the latest 5am trend, get up with the lark and to find a couple more precious hours in your day? Does it have real implications – and does it even matter at all? What is the problem with having six hours sleep? The long-term impacts of sleep deprivation So are people who only sleep six hours a night doomed? Strategies to improve sleep quality If you consistently have less than six hours' sleep, the chances are that you are risking health problems. 'On the surface, you will be moody, frustrated and irritated,' says Maryanne Taylor, a sleep consultant from sleep consultancy The Sleep Works. 'On a deeper level, you'll be raising your risks of stress and anxiety – these have a bidirectional relationship to your sleep.' Three key problems are: Sophie Bostock is a sleep scientist and behavioural psychologist. 'We know that poor sleep and mental health are inextricably linked,' she says. 'Poor sleepers are twice as likely to develop anxiety and depression than good sleepers. 'While this is no surprise to those who lie awake at night worrying, there is some good news, too – improving one's sleep will benefit one's mental health.' 'Our brains evolved to see sleep loss as a warning sign,' says Bostock. 'Our ancestors were more likely to be kept awake by predators than by scrolling through their phones, so we respond to short sleep by going into high alert.' Hence, we get more sensitive to potential foes. 'We are more likely to interpret neutral faces as threatening and to withdraw from social situations, diverting resources from the more rational part of our brain and decision-making capacity,' she says. 'Without enough sleep, in the longer term, we struggle to focus, to learn and remember, to empathise and make logical, sensible decisions,' says Bostock. Insomnia is linked to a wide variety of conditions, from obesity to Type 2 diabetes and even Alzheimer's. The reasons were discussed in the May 2019 edition of the journal Experimental Psychology, with theories ranging from blood vessels littered with fatty deposits, to 'cellular garbage' in the brain. According to the research, people who sleep fewer than seven hours a night have a significantly raised level of molecules called microRNAs, which suppress the protein content of cells and have previously been linked to inflammation and poor blood vessel health. Not getting enough sleep makes you more likely to gain weight, according to the analysis of 36 studies, discussed in the journal Obesity. Various studies have shown that poor sleep disrupts the productions of the hormones ghrelin and leptin – the hormones that control hunger. Thus, insomniacs crave fatty, starchy and sugary foods, potentially eating hundreds of extra calories a day in refined carbohydrates The daytime exhaustion means you can't be bothered to exercise and so your weight gain spirals, as does a cascade into other conditions such as diabetes and heart disease. People with a chronic lack of sleep significant risk an increase in Type 2 diabetes, according to a report in the journal Diabetes Care. Patients who suffered poor sleep (defined as fewer than five hours a night) for a year or longer had three times the risk of those who slept six hours or more. As with obesity (also linked to Type 2 diabetes), the underlying cause is thought to involve disruption of the body's normal hormonal regulation, but in this case it results from insufficient sleep. It's well known that sleep is necessary for a healthy immune system, the part of our make-up which tackles antigens, or foreign invaders, as well as 'T cells': white blood cells which destroy virus carrying cells. One study showed that subjects who slept fewer than seven hours a night were three times as likely to catch colds than those who got the full eight, or more. Much modern research indicates that insomnia raises the risk of Alzheimer's. The Harvard Medical School report revealed that people with sleep impairments were nearly 1.7 times as likely to develop cognitive impairments than those without. Researchers from the University of Tennessee noted that chronic insomnia was tied to a 1.5 times higher risk of kidney decline, and an even steeper increase in risk of kidney failure: 2.4 times. A comprehensive report linking insomnia with high cholesterol and blood pressure was published in 2019 by a top American university. People who don't get enough sleep also have raised levels of stress hormones and substances that indicate inflammation, a key cause of cardiovascular disease. Fewer than four hours' a night sleep could double a woman's risk of dying of heart disease. But before you take to your bed in despair, Taylor draws a distinction between short periods of six hours' sleep or fewer, and longer-term sleep deprivation. 'If a small burst of stress (a job interview, for example) impacts the amount of hours you get, it's unlikely to mean you have an ongoing sleep problem. We all have these blips.' Bostock also says there is no reason to panic. 'All these chronic conditions are multifactorial, so we need loads of subjects to work out the rule of the impact of confounding factors. In the short term studies, typically healthy people recover after several days of proper sleep.' The first step is to make sure you have the bases covered: that your bedroom is dark, quiet and at optimum temperature – between 16C to 18C. Your bedding should be comfortable and, ideally, made of natural fibres. Cut out coffee after midday, and have a proper wind-down routine. If you are suffering with chronic sleep problems, attending to sleep hygiene may not be enough, however. 'We can become a slave to hygiene and in some ways it can be counterproductive,' says Taylor. 'There is so much paraphernalia out there: Spray this! Drink this! The fact is that people who sleep well don't actually do anything. Sleep is an innate process, and we all can do it: it's just about creating the conditions in our brain.' Instead, Taylor suggests adopting a more flexible mindset. 'Bedtime procrastination can cause sleep anxiety,' she says. 'Firstly, it really is OK to stop looking at your work emails after 7pm.' Waking up in the night is part of the natural process, says Bostock. 'Your sleep goes in 90-minute cycles, and people tend to wake up more as they get older.' But problems arise if you wake up and have difficulty falling back to sleep again. 'Many people who wake up at night tell themselves: I have to stay in bed,' says Taylor. 'But this can be the crux of maintaining sleep problems.' Taylor suggests making what she calls a 'nest' outside your bed. 'A comfortable chair or beanbag, lit with dim light, with a book or your headphones, and not your phone,' she says. 'When you feel sleepy, go back to bed. If you have to get up a few times a night to do this, that's fine.' Anyone who's had a run of broken nights will agree with Taylor's philosophy that sleep doesn't do well under pressure. 'Have a look at your sleep narrative,' she says. 'If you are telling yourself: 'I'm a terrible sleeper', 'I won't be able to manage tomorrow,' this can be very powerful and only serve to make you more stressed and less able to drop off. You need to step out of your own way.' Instead, tell yourself: 'It's OK, I will survive', and 'I'm a good sleeper, I'm just having a bad night.' Sleeping well is not just about what happens in the hours of darkness: you set yourself up for the next night the minute you open your eyes that day. 'What do you do the minute you wake up?' asks Taylor. 'If you feel rubbish, do you keep pressing snooze until you jump up in a panic? Do you pick up your phone, and are catapulted brutally into the next day? Of course your sleep will be impacted.' Instead, she recommends easing into the day with a cup of tea, in the light. 'As soon as you wake up, aim to get lots of light into your eyes,' she says. 'Go outside if you can, if not, or at least sit near a window. This banishes the sleep hormone, melatonin, and activates the cortisol awakening response in your brain telling you that the day has begun.' Miranda Levy is the author of The Insomnia Diaries: How I Learned to Sleep Again Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Associated Press
16 minutes ago
- Associated Press
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purchased or otherwise acquired stock of Zenas pursuant and/or traceable to Zenas' registration statement for the initial public offering held on or about September 13, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - June 8, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zenas BioPharma, Inc. ('Zenas' or the 'Company') (NASDAQ: ZBIO) and reminds investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Zenas BioPharma materially overstated the amount of time it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants' public statements were materially false and misleading at all relevant times and negligently prepared. When the true details entered the market, the lawsuit claims that investors suffered damages. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zenas' conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zenas BioPharma class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Associated Press
16 minutes ago
- Associated Press
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, June 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the 'Class Period'), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Organon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Organon class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 22, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Organon's priorities, particularly, related to capital allocation through quarterly dividends. Notably, defendants concealed the high priority of Organon's debt reduction strategy following Organon's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Organon class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
